Table 1 Baseline demographics and clinical characteristics for the two study arms
Characteristic | 2DR | 3DR | P value |
|---|---|---|---|
Age, y, median (range) | 31 (24–38) | 31 (24.25–40) | 0.768 |
Male | 27 (100%) | 23 (82.14%) | 0.051 |
Mode of transmission | |||
MSM | 22 (81.48%) | 20 (68.97%) | 0.38 |
Heterosexual | 5 (18.51%) | 7 (25.00%) | 0.561 |
IDU | 0 (0%) | 1 (3.57%) | 1.000 |
Hepatitis B | 0 (0%) | 3 (10.71%) | 0.236 |
Hepatitis C | 0 (0%) | 0 (0%) | – |
Opportunistic infections | 12 (44.44%) | 4 (14.29%) | 0.033 |
Pneumocystosis | 5 (18.51%) | 4 (14.29%) | 0.954 |
Penicillium Malneffei | 4 (14.81%) | 0 (0%) | 0.051 |
Cryptococcus | 0 (0%) | 1 (3.57%) | 1.000 |
Candida | 3 (11.11%) | 1 (3.57%) | 0.352 |
Tuberculosis | 1 (3.7%) | 0 (0%) | 0.491 |
Cytomegalovirus | 7 (25.93%) | 2 (7.14%) | 0.129 |
EB virus | 4 (14.81%) | 1 (3.57%) | 0.305 |
Bacterial infection | 4 (14.81%) | 3 (10.71%) | 0.916 |
CD4/CD8 ratio | 0.25 ± 0.17 | 0.36 ± 0.19 | 0.031 |
CD4 + count (cells/μL) | |||
Mean | 222.07 ± 176.67 | 326.55 ± 194.56 | 0.044 |
≤ 200 (cells/μL) | 13 (48.15%) | 5 (17.86%) | 0.017 |
> 200 (cells/μL) | 14 (51.85%) | 22 (78.57%) | 0.037 |
HIV-1 RNA ( copies/mL) | |||
Median (range) | 61,100 (33,500–229,000) | 42,600 (22,650–91,200) | 0.167 |
≤ 100,000 (copies/mL) | 18 (66.67%) | 24 (85.71%) | 0.179 |
> 100,000 (copies/mL) | 9 (33.33%) | 4 (14.29%) | 0.179 |
ALT | 17.7 (12–24) | 20.45 (14.25–30.3) | 0.210 |
AST | 19 (17.5–25.2) | 21.40 ± 5.14 | 0.705 |
Creatinine | 75 (67–91) | 77.14 ± 16.04 | 0.926 |
Cystatin | 0.99 ± 0.38 | 0.89 (0.79–1) | 0.076 |
Urea | 3.94 (3.5–4.4) | 4.19 ± 1.15 | 0.495 |
CHOL | 3.79 ± 1.05 | 4.09 ± 1.18 | 0.328 |
HDL | 0.99 (0.77–1.15) | 1.06 ± 0.37 | 0.421 |
LDL | 2.24 ± 0.91 | 2.60 ± 0.69 | 0.109 |
TG | 131 ± 0.66 | 1.57 (0.7–1.96) | 0.441 |
eGFR | 100.56 ± 21.18 | 101.29 ± 14.23 | 0.905 |